Active Ingredient History
Lapatinib is a small molecule and a member of the 4-anilinoquinazoline class of kinase inhibitors. It is present as the monohydrate of the ditosylate salt (trade name TYKERB). Lapatinib is dual inhibitor of the EGFR (epidermal growth factor receptor; also called HER1 or ErbB1) and HER2 receptor tyrosine kinases. Lapatinib was developed by GlaxoSmithKline, however, Novartis subsequently acquired all the rights to the drug from GlaxoSmithKline. TYKERB is indicated in combination therapy for the treatment of metastatic breast cancer that overexpresses the HER2 receptor. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma (Phase 2)
Adenocarcinoma of Lung (Phase 2)
alpha-Fetoproteins (Phase 2)
Angiogenesis Modulating Agents (Phase 2)
Ascites (Phase 2)
Astrocytoma (Phase 1/Phase 2)
Bile Duct Neoplasms (Phase 2)
Biliary Tract Neoplasms (Phase 2)
Biomarkers (Phase 2)
Brachiocephalic Trunk (Phase 2)
Brain Neoplasms (Phase 3)
Breast Diseases (Phase 2)
Breast Neoplasms, Male (Phase 3)
Capecitabine (Phase 3)
Carcinoma (Phase 2)
Carcinoma, Adenoid Cystic (Phase 2)
Carcinoma, Ductal, Breast (Phase 2)
Carcinoma, Hepatocellular (Phase 4)
Carcinoma, Non-Small-Cell Lung (Phase 4)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Carcinoma, Verrucous (Phase 2)
Carcinosarcoma (Phase 2)
Cardiotoxicity (Phase 2)
Catheters (Phase 2)
Chemoembolization, Therapeutic (Phase 2)
Cholangiocarcinoma (Phase 3)
Chordoma (Phase 2)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 2)
Cystectomy (Early Phase 1)
Cytochrome P-450 Enzyme System (Phase 1)
Death (Phase 1)
Digestive System Neoplasms (Phase 3)
Disease Progression (Phase 2)
Drugs, Investigational (Phase 2)
Drug Therapy (Phase 2)
Drug Therapy, Combination (Phase 1/Phase 2)
Endometrial Neoplasms (Phase 2)
Endothelium (Phase 2)
Ependymoma (Phase 1/Phase 2)
Epidermal Growth Factor (Phase 3)
Esophageal Neoplasms (Phase 4)
Esophageal Squamous Cell Carcinoma (Phase 2)
Extremities (Phase 2)
Fallopian Tube Neoplasms (Phase 3)
Gallbladder Neoplasms (Phase 2)
Gastrointestinal Neoplasms (Phase 3)
Gastrointestinal Stromal Tumors (Phase 2)
General Surgery (Phase 3)
Genes, erbB-1 (Phase 2)
Genes, erbB-2 (Phase 1)
Genes, Neurofibromatosis 2 (Early Phase 1)
Gestational Trophoblastic Disease (Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Gliosarcoma (Phase 2)
Graft vs Host Disease (Phase 2)
Graves Ophthalmopathy (Phase 3)
Hamartoma (Phase 3)
Head and Neck Neoplasms (Phase 3)
Health Services for the Aged (Phase 2)
Healthy Volunteers (Phase 1)
Hepatectomy (Phase 2)
Hypopharyngeal Neoplasms (Phase 2)
Immune Checkpoint Inhibitors (Phase 3)
Immunotherapy (Phase 3)
Inflammatory Breast Neoplasms (Phase 2/Phase 3)
Intestinal Neoplasms (Phase 3)
Lapatinib (Phase 3)
Leukemia, B-Cell (Phase 2)
Liver Neoplasms (Phase 2)
Liver Transplantation (Phase 1/Phase 2)
Lung Diseases (Phase 2)
Lung Neoplasms (Phase 4)
Lymphoma (Phase 1/Phase 2)
Lymphoma, B-Cell (Phase 1/Phase 2)
Lymphoma, Follicular (Phase 1/Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 4)
Lymphoma, Large-Cell, Anaplastic (Phase 1/Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 1/Phase 2)
Lymphoma, T-Cell (Phase 4)
Lymphoma, T-Cell, Peripheral (Phase 1/Phase 2)
Medulloblastoma (Phase 2)
Melanoma (Phase 3)
Microsatellite Instability (Phase 2)
Molecular Targeted Therapy (Phase 2)
Mouth Neoplasms (Phase 1)
Mutation (Phase 2)
Nasopharyngeal Carcinoma (Phase 3)
Nasopharyngeal Neoplasms (Phase 2)
Neoadjuvant Therapy (Phase 2)
Neoplasm Metastasis (Phase 2/Phase 3)
Neoplasms ()
Neuroblastoma (Phase 2)
Neurofibromatosis 2 (Phase 2)
Neuroma, Acoustic (Phase 2)
Oligodendroglioma (Phase 1/Phase 2)
Oncogene Proteins (Phase 2)
Osteosarcoma (Phase 2/Phase 3)
Ovarian Diseases (Phase 2)
Ovarian Neoplasms (Phase 4)
Pancreatic Neoplasms (Phase 2)
Pharmaceutical Preparations (Phase 2)
Pharmacokinetics (Phase 2)
Pituitary Neoplasms (Phase 2)
Progression-Free Survival (Phase 3)
Prolactinoma (Phase 2)
Prostatic Neoplasms (Phase 2)
Radiation Injuries (Phase 2)
Radiotherapy (Phase 2)
Radiotherapy, Intensity-Modulated (Phase 2)
Recurrence (Phase 2)
Respiratory Tract Diseases (Phase 2)
Rhabdomyosarcoma (Phase 1/Phase 2)
Salivary Gland Neoplasms (Phase 2)
Sarcoma (Phase 3)
Small Cell Lung Carcinoma (Phase 3)
Spinal Cord Neoplasms (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Diseases (Phase 3)
Stomach Neoplasms (Phase 4)
Survival (Phase 2)
Therapeutics (Phase 2)
Thoracic Neoplasms (Phase 2)
Thymoma (Phase 2)
Thyroid Gland (Phase 2)
Thyroid Neoplasms (Phase 3)
Tongue Neoplasms (Phase 2)
Triple Negative Breast Neoplasms (Phase 3)
Urinary Bladder Neoplasms (Phase 2/Phase 3)
Uterine Cervical Neoplasms (Phase 4)
Uterine Neoplasms (Phase 2)
Wounds and Injuries (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
